Insider Transactions in Q1 2024 at Recursion Pharmaceuticals, Inc. (RXRX)
Insider Transaction List (Q1 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 09
2024
|
Blake Borgeson Director |
SELL
Open market or private sale
|
Direct |
20,054
-0.14%
|
$260,702
$13.51 P/Share
|
|
Jan 09
2024
|
Dean Y Li Director |
SELL
Open market or private sale
|
Indirect |
29,000
-3.23%
|
$377,000
$13.84 P/Share
|
|
Jan 03
2024
|
Christopher Gibson Chief Executive Officer |
SELL
Open market or private sale
|
Indirect |
25,000
-100.0%
|
$225,000
$9.5 P/Share
|
|
Jan 03
2024
|
Christopher Gibson Chief Executive Officer |
BUY
Conversion of derivative security
|
Indirect |
25,000
+50.0%
|
-
|
|
Jan 03
2024
|
Christopher Gibson Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
30,853
-3.75%
|
$277,677
$9.49 P/Share
|
|
Jan 03
2024
|
Christopher Gibson Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
31,250
+3.66%
|
$62,500
$2.48 P/Share
|
|
Jan 03
2024
|
Christopher Gibson Chief Executive Officer |
SELL
Bona fide gift
|
Direct |
10,000
-1.25%
|
-
|
|
Jan 03
2024
|
Christopher Gibson Chief Executive Officer |
BUY
Conversion of derivative security
|
Direct |
10,000
+1.23%
|
-
|
|
Jan 02
2024
|
Dean Y Li Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,203
+0.09%
|
-
|
|
Jan 02
2024
|
Zavain Dar Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,393
+2.46%
|
-
|
|
Jan 02
2024
|
R. Martin Chavez Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,900
+3.17%
|
-
|